"California will start selling insulin next year after striking out on its own in a bold deal to lower the cost of prescription drugs, making it the first state in the nation to do so. The state will offer low-cost insulin through CalRx, a state program designed to provide affordable life-saving drugs in California. Through the California program, insulin will be available starting in 2026 to state pharmacies for $45 for a five pack of insulin pens, with a suggested retail price of $55."
"Production of the drug will be handled by nonprofit pharmaceutical company Civica Rx through a $50 million deal the state struck in 2023. The partnership will eventually produce three forms of insulin, equivalent to namebrands Lantus, Humalog, and Novolog. The program is starting with glargine, a generic version of the drug Lantus, which will be available in January. The CalRx insulin will be produced at Civica's manufacturing plant in Virginia."
California will begin selling insulin through the state-run CalRx program, offering a five-pack of insulin pens to state pharmacies for $45 with a suggested retail price of $55. The price will apply to everyone regardless of insurance. Production will be managed by nonprofit Civica Rx under a $50 million agreement, with manufacturing at Civica's Virginia plant. The partnership plans to produce three insulin formulations equivalent to Lantus, Humalog, and Novolog, starting with glargine, a generic Lantus, available in January. CalRx originated as a 2019 executive order and became law in 2020; the program previously lowered naloxone prices.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]